$4.0583
0.0683[1.71%]
Last update: 9:16AM Get Real Time Here
Cardiff Oncology
(NASDAQ:CRDF)Cardiff Oncology Stock (NASDAQ:CRDF), Analyst Ratings, Price Targets, Predictions
Cardiff Oncology Inc has a consensus price target of $9, established from looking at the 15 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Piper Sandler, and HC Wainwright & Co. on March 6, 2024, March 1, 2024, and August 11, 2023. With an average price target of $11 between HC Wainwright & Co., Piper Sandler, and HC Wainwright & Co., there's an implied 172.28% upside for Cardiff Oncology Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
Baird
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cardiff Oncology
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/06/2024 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 246.53% | HC Wainwright & Co. | Raghuram Selvaraju | $12 → $14 | Maintains | Buy | Get Alert |
| 03/01/2024 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 73.27% | Piper Sandler | Joseph Catanzaro | $5 → $7 | Maintains | Overweight | Get Alert |
| 08/11/2023 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 197.03% | HC Wainwright & Co. | Raghuram Selvaraju | $13 → $12 | Maintains | Buy | Get Alert |
| 08/08/2023 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 221.78% | HC Wainwright & Co. | Raghuram Selvaraju | $14 → $13 | Maintains | Buy | Get Alert |
| 05/09/2023 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 246.53% | HC Wainwright & Co. | Raghuram Selvaraju | $15 → $14 | Maintains | Buy | Get Alert |
| 03/29/2023 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 271.29% | HC Wainwright & Co. | Raghuram Selvaraju | → $15 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 271.29% | HC Wainwright & Co. | Raghuram Selvaraju | $14 → $15 | Maintains | Buy | Get Alert |
| 09/16/2022 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 246.53% | HC Wainwright & Co. | Raghuram Selvaraju | $22 → $14 | Maintains | Buy | Get Alert |
| 09/13/2022 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 23.76% | Piper Sandler | Joseph Catanzaro | $7 → $5 | Maintains | Overweight | Get Alert |
| 08/29/2022 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 48.51% | Baird | Joel Beatty | $9 → $6 | Maintains | Outperform | Get Alert |
| 05/09/2022 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 444.55% | HC Wainwright & Co. | Raghuram Selvaraju | $25 → $22 | Maintains | Buy | Get Alert |
| 02/28/2022 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 518.81% | HC Wainwright & Co. | Raghuram Selvaraju | $26 → $25 | Maintains | Buy | Get Alert |
| 12/08/2021 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 370.3% | Baird | Joel Beatty | — | Initiates | → Outperform | Get Alert |
| 08/10/2021 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 543.56% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
| 05/10/2021 | CRDF | Buy Now | Cardiff Oncology | $4.04 | 518.81% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Cardiff Oncology (CRDF)?
The latest price target for Cardiff Oncology (NASDAQ: CRDF) was reported by HC Wainwright & Co. on March 6, 2024. The analyst firm set a price target for $14.00 expecting CRDF to rise to within 12 months (a possible 244.97% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cardiff Oncology (CRDF)?
The latest analyst rating for Cardiff Oncology (NASDAQ: CRDF) was provided by HC Wainwright & Co., and Cardiff Oncology maintained their buy rating.
When was the last upgrade for Cardiff Oncology (CRDF)?
There is no last upgrade for Cardiff Oncology.
When was the last downgrade for Cardiff Oncology (CRDF)?
There is no last downgrade for Cardiff Oncology.
When is the next analyst rating going to be posted or updated for Cardiff Oncology (CRDF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiff Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiff Oncology was filed on March 6, 2024 so you should expect the next rating to be made available sometime around March 6, 2025.
Is the Analyst Rating Cardiff Oncology (CRDF) correct?
While ratings are subjective and will change, the latest Cardiff Oncology (CRDF) rating was a maintained with a price target of $12.00 to $14.00. The current price Cardiff Oncology (CRDF) is trading at is $4.06, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.